Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsies.

Autor: Alienor Berges, Jonathan Bullman, Stewart Bates, David Krull, Nicola Williams, Chao Chen

Publikováno v: PLoS ONE, Vol 10, Iss 2, p e0117355 (2015)

Amyotrophic Lateral Sclerosis (ALS) is a rare and fatal neurodegenerative disease with a high unmet medical need. In this context, a potential therapy should be brought to patients in the most expeditious way and early exploration of pharmacology is

Externí odkaz: https://doaj.org/article/ecd3addcfebe4537981d48fc83135822

Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti‐CD3ε mAb in new‐onset type 1 diabetes mellitus patients

Autor: Ruth M Barnard, David Inman, Kevin R. Page, Bart Keymeulen, Quentin Leirens, Alexander MacDonald, Antonella Napolitano, Kim Brown, David Lanham, Jonathan Bullman, Minesh Patel, André van Maurik, Enrica Mezzalana, Caroline O. S. Savage, Georgios Vlasakakis, Stefano Zamuner

Publikováno v: British Journal of Clinical Pharmacology. 85:704-714

Aims This paper describes the pharmacological findings from a study where otelixizumab, an anti-CD3ɛ mAb, was dosed in new onset Type 1 diabetes mellitus (NOT1DM) patients. This is the first time that the full dose-response of an anti-CD3ɛ mAb has

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b3cc8aff306a4ae44c500abe35002d5
https://doi.org/10.1111/bcp.13842

Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study

Autor: Jonathan Bullman, Therese Collingwood, Robert Bissonnette, Lakshmi S. Vasist, Tomoko Maeda-Chubachi, Geng Chen

Publikováno v: Clinical Pharmacology in Drug Development. 7:524-531

Tapinarof cream is a novel topical nonsteroidal agent that represents a unique class of anti-inflammatory molecules targeting the aryl hydrocarbon receptor. Study 201851 was an open-label, 2-cohort sequential study that assessed the systemic pharmaco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e3a5017484dcd80147d9148bd484ce2
https://doi.org/10.1002/cpdd.439

The relative bioavailability of 2 prototype fixed-dose combination formulations for amlodipine and rosuvastatin in healthy white and Chinese subjects

Autor: Jonathan Bullman, Shashidhar Joshi, Shiva G. Kapsi, Htar H. Nwe, Annie Stylianou

Publikováno v: Clinical Pharmacology in Drug Development. 5:131-140

A fixed-dose combination (FDC) may improve patient compliance and clinical outcomes in the management of cardiovascular risk in hypertensive and dyslipidemic patients. The study (NCT02075619) evaluated the bioavailability of 2 prototype FDC tablet fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ff5a713f6b3c2f4c404079526d81f37
https://doi.org/10.1002/cpdd.214

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis : a randomised, double-blind, placebo-controlled, phase 2 trial

Autor: Stephen DeWall, Karen E. Morrison, Alain Destée, Andrea Calvo, Annelot M. Dekker, Francesca Barbieri, Philip Van Damme, James D. Berry, Robert D. Henderson, Claude Desnuelle, Johannes Dorst, Linda O. Nichols, Jerzy Daniluk, Sonja Koerner, Adriano Chiò, Kristiana Salmon, Pierre-François Pradat, Albert C. Ludolph, Genevieve Matte, Harutoshi Fujimura, Gaëlle Bruneteau, Stewart Bates, Giuseppe Fuda, Torsten Grehl, Usha Gungabissoon, Andrea Sylvia Winkler, Byung Jo Kim, Eleanor Ramsey, Christen Shoesmith, Peggy Ho, Matthew C. Kiernan, Rodrigo Refoios Camejo, Saiju Jacob, Rob Stubbs, Thomas M. Ringer, Jonathan Bullman, Stephan A Botez, Michael A. van Es, Xenia Kobeleva, Stefano Milleri, Wim Robberecht, William Huynh, Mary Lou Watson, Mieko Ogino, Seung Hyun Kim, Chris Parkinson, Diane Boswell, Stephen J. Kolb, Jeremy M. Shefner, Katja Kollewe, Jane R. Temple, Paul Rees, Julian Grosskreutz, Deven Chauhan, K. Nishiyama, Leonard H. van den Berg, Marloes Stam, Susanne Petri, Rami Massie, Darryl Menezes, Tino Prell, Anthony Lynch, Raul Juntas-Morales, Andreas Funke, P. Nigel Leigh, Lawrence Korngut, Angela Genge, Cathy Alsop, Margie C. Zoing, Arseniy Lavrov, Rajat Mohindra, Anne E. Visser, Susanne Abdulla, Veronique Danel-Brunaud, William Camu, Matt Davies, Amy Lee, Erik Steinberg, Lorne Zinman, Jeffrey Price, Marie Helene Soriani, Matthew S Devine, Vincent Meininger, Géraldine Lautrette, Herman Sullivan

Publikováno v: Lancet Neurology, 16(3), 208. Lancet Publishing Group
The Lancet Neurology
The Lancet Neurology, Elsevier, 2017, 16 (3), pp.208-216. ⟨10.1016/S1474-4422(16)30399-4⟩

Summary Background Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the pathophysiology of amyotrophic lateral sclerosis (ALS). A monoclonal antibody against Nogo-A showed a positive effect in the SOD1 G93A mouse model of ALS, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84786f0743df2f63aa43471c398c75f9
https://dspace.library.uu.nl/handle/1874/348903